*Mission*
Elsevier is committed to making genuine contributions to the science and
health communities.
Elsevier. Building Insights. Breaking Boundaries.

 Home </wps/find/homepage.cws_home> | Site map
</wps/find/sitemap.cws_home/sitemap> | Elsevier websites
</wps/find/elsevierwebsites.cws_home/elsevierwebsites> | Alerts
</wps/find/home_content.cws_home/alertingservices>
	Elsevier 		

	Product information search 	
	Search all Elsevier sites 	
Search <javascript:submitSearchForm(document.forms['searchForm'])> 	
Advanced Product Search
</wps/find/advproductsearch.cws_home?action=product_search&search=no>

	

Go to Elsevier home page </wps/find/homepage.cws_home>

	
	Products
</wps/find/subject_area_browse.cws_home/?sh1State=-null-SAR-SAA-SAC-SAD-SAF-SA1-SAI-SAJ-SAK-SAQ-SAP-SAB-SAE-SAL-SAN-SAO-SAG-SAH-SAM&sh2State=&allParents=y&showAll=y>
	

	Cancer Letters
</wps/find/journaldescription.cws_home/506050/authorinstructions?navopenmenu=-2>
	

	Journal information

	Product description
</wps/find/journaldescription.cws_home/506050/description#description> 	

	Editorial board
</wps/find/journaleditorialboard.cws_home/506050/editorialboard#editorialboard>
	

	Audience </wps/find/journalaudience.cws_home/506050/description#audience> 	

	Abstracting/indexing
</wps/find/journalabstracting.cws_home/506050/abstracting#abstracting> 	

	Special issues and supplements
</wps/find/journalspecialissues.cws_home/506050/specialissues#specialissues>
	

	Peer review policy
</wps/find/journalrelatedinfo.cws_home/506050/preface1> 	

	Subscription information

	Bibliographic and ordering information
</wps/find/journalbibliographicinfo.cws_home/506050/description#bibliographicinfo>
	

	Conditions of sale
</wps/find/journalconditionsofsale.cws_home/506050/conditionsofsale#conditionsofsale>
	

	Dispatch dates
</wps/find/journaldispatchdates.cws_home/506050/dispatchdates#dispatchdates>
	

	Journal-related information

	Impact factor
</wps/find/journalimpactfactors.cws_home/506050/description#impactfactors> 	

	Most downloaded articles
<javascript:openWindow("http://top25.sciencedirect.com/?journal_id=03043835","topdownload")>
	

	Other journals in same subject area
</wps/find/products_in_subject_and_group.cws_home/506050> 	

	Support & contact </wps/find/supportfaq.cws_home/overview> 	

	About Elsevier </wps/find/intro.cws_home/ataglance> 	

	Select your view
</wps/find/journaldescription.cws_home/506050/authorinstructions?navopenmenu=4>
	

	

			
	
	CANCER LETTERS	
		
	
An international journal providing a forum for original and pertinent
contributions in cancer research

*Guide for Authors*

*Types of papers *

/Cancer Letters/ welcomes submissions of original research papers and
Minireviews. The act of submitting a manuscript to the journal carries
with it the right to publish that paper. The main object of the journal
is the publication of papers with particular reference to the human
species. These should appeal to clinicians and research workers alike.
Original research papers should deal with original research not
previously published or being considered for publication elsewhere.
Minireviews should provide concise overviews of the current research
and/or clinical status of the topics under discussion. They should
discuss published data. Minireviews should not present primary
unpublished data. /Cancer Letters/ does not publish Case Reports.

*Ethics and Procedures*

The editors and publisher of this Journal believe that there are
fundamental principles underlying scholarly or professional publishing.
While this may not amount to a formal "code of conduct", these
fundamental principles with respect to the authors' paper are that the
paper should:
* be the authors' own original work, which has not been previously
published elsewhere
* reflect the authors' own research and analysis and do so in a truthful
and complete manner,
* properly credit the meaningful contributions of co-authors and
co-researchers,
* not be submitted to more than one journal for consideration (ensuring
it is not under redundant simultaneous peer review), and
* be appropriately placed in the context of prior and existing research.

Of equal importance are ethical guidelines dealing with research methods
and research funding, including issues dealing with informed consent,
research subject privacy rights, conflicts of interest, and sources of
funding. While it may not be possible to draft a "code" that applies
adequately to all instances and circumstances, we believe it useful to
outline our expectations of authors and procedures that the Journal will
employ in the event of questions concerning author conduct. Relevant
conflicts of interest should be disclosed (see External link
http://www.elsevier.com/wps/find/authorshome.authors/conflictsofinterest).

*Submission of manuscripts*

/Cancer Letters/ has moved to an online submission and review system.
Manuscripts should be submitted online at External link
http://www.ees.elsevier.com/can and the instructions on the site should
be closely followed. Authors may submit manuscripts and track their
progress through to final decision. Reviewers can download manuscripts
and submit their reports to the Managing Editors.

Authors unable to submit online should contact the Editorial Office:


Cancer Letters Editorial Office
Elsevier Ltd
The Boulevard
Langford Lane
Oxford OX5 1GB
U.K.
Tel : +44 (0)1865 843203
Fax : +44 (0)1865 843992
Email :cancerletters@elsevier.com <mailto:cancerletters@elsevier.com >

Submission of an article to /Cancer Letters/ implies that the work
described has not been published previously (except in the form of an
abstract or as part of a published lecture or academic thesis), that it
is not under consideration for publication elsewhere, that its
publication is approved by all authors and tacitly or explicitly by the
responsible authorities where the work was carried out, and that, if
accepted, it will not be published elsewhere in the same form, in
English or any other language, without the written consent of the Publisher.

Manuscripts should be submitted online at External link
http://www.ees.elsevier.com/can; should be in English; should not be
longer than 6 printed pages (approx. 12 double-spaced type written
pages) including the space needed for illustrations. Authors' full
names, academic or professional affiliations, and addresses should be
included on the first page. The name, postal address, email address,
phone and FAX numbers of the corresponding author should be provided.
Authors should supply the names and email addresses of up to 5 potential
reviewers for their manuscript. To provide an international perspective,
no more than 2 potential reviewers should be from the same country.
Please do not suggest reviewers from your own institution, previous or
current collaborators or Editorial Board members. Without reviewer
suggestions, processing of the manuscript may be delayed. Please do not
contact any reviewers that you have suggested.

Online submission guidelines can be followed at External link
http://www.ees.elsevier.com/can. Via this website you will be guided
stepwise through the creation and uploading of the various files. The
system automatically converts source files into a single Adobe Acrobat
PDF version of the article, which is used in the peer review process.
Please note that although manuscript source files are converted to PDF
at submission for the review process, these source files are needed for
further processing after acceptance. All correspondence, including
notification of the Editor's decision and requests for revision, takes
place by email and via the author's homepage, removing the need for a
hard-copy paper trail.

*Manuscript preparation*

Please strive for a professionally prepared manuscript of high technical
and scientific quality. Many reviewers are overwhelmed with review
requests. Our experience is that they are more likely to agree to review
a well prepared manuscript.

Articles should be submitted in the following order : Title, Abstract,
Introduction, Materials and Methods, Results, Discussion,
Acknowledgements, References.

All submissions must be accompanied by a covering letter in which the
significance of the results is outlined in no more than 5 sentences.

Title must address the main result of the study and preferably not
exceed 185 characters, including spaces. Extraneous words such as
'study' 'investigation', 'analysis', etc, should be avoided.

_Abstract_. A concise and factual abstract not exceeding 80-100 is
required, followed by 3-6 indexing terms (keywords). The abstract should
briefly state the purpose of the research, the principal results and
major conclusions. An abstract is often presented separately from the
article, so it must be able to stand alone.

_Tables_ should be typed, with double spacing, each on a separate sheet,
numbered consecutively with Roman numerals, and should only contain
horizontal lines. A short descriptive heading should be given above each
table, and any footnotes and explanations underneath.

_Figures_ must be numbered and keyed into the text. For advice on
correctly formatting electronic images, please refer to External link
http://authors.elsevier.com. For illustrations that cannot be submitted
electronically, please send them by post to the Editorial Office. The
author's name, the figure number and an arrow identifying orientation
should be appended to the reverse of each illustration. Line drawings
(including graphs) must be in black ink on a white background.
Alternatively, sharp photographs on glossy paper may be provided. The
lettering should be large enough to permit photographic reproduction.
Halftone illustrations may be included, which should be submitted as
black and white prints on glossy paper and have as much contrast as
possible. All legends should be typed on a separate sheet of paper.
Composite illustrations should be sensibly and compactly arranged as a
plate, without leaving much empty white space between the different
elements.

Illustrations should be designed for use in either a single column
(7.5cm) or a double column (16cm). Actual magnification of all
photomicrographs should be indicated by a micron bar or in the legend.

Please make sure that artwork files are in an acceptable format (TIFF,
EPS or MS Office files) and with the correct resolution. If, together
with your accepted article, you submit usable electronic colour figures
then Elsevier will ensure, at no additional charge, that these figures
will appear in colour on the Web (e.g. ScienceDirect and other sites)
regardless of whether or not these illustrations are reproduced in
colour in the printed version. For colour reproduction in print, you
will receive information regarding the costs from Elsevier after receipt
of your accepted article. Please indicate your preference for colour in
print or on the Web only. For further information on the preparation of
electronic artwork, please see External link
http://authors.elsevier.com/artwork.

_References_ should be numbered and listed on a separate sheet. Indicate
references by number(s) in square brackets in line with the text. The
actual authors can be referred to, but the reference number(s) must
always be given.

Example: "?.. as demonstrated [3,4]. Barnaby and Jones [5] obtained a
different result?."

List: Number the references (numbers in square brackets) in the list in
the order in which they appear in the text.

Examples:
Reference to a journal publication:
[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a
scientific article, J. Sci. Commun. 163 (2000) 51-59

Reference to a book:
[2] W. Strunk Jr., E.B. White, The Elements of Style, third ed.,
Macmillan, New York, 1979.

Reference to a chapter in an edited book:
[3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of
your article, in: B.S. Jones, R.Z. Smith (Eds.), Introduction to the
Electronic Age, E-Publishing Inc., New York, 1999, pp281-304.

Supplementary data is accepted by /Cancer Letters/ to support and
enhance your scientific research. Supplementary files offer the author
additional responsibilities to publish supporting applications, movies,
animation sequences, high-resolution images, background datasets, sound
clips and more. Supplementary files will be published online alongside
the electronic version of your article in Elsevier Web products,
including ScienceDirect: External link http://www.sciencedirect.com. In
order to ensure that your submitted material is directly usable, please
ensure that data is provided in one of our recommended file formats.
Authors should submit the material in electronic format together with
the article and supply a concise and descriptive caption for each file.
For more detailed instructions, please visit our artwork instruction
pages at the Author Gateway at External link
http://authors.elsevier.com/artwork.

Authors In Japan please note: if you would like information about how to
have the English of your paper checked, corrected and improved (before
submission), please contact our Tokyo office who will inform you of the
services provided by language correctors:

Elsevier, 9-15, Higashi-Azabu 1-chome, Minato-ku, Tokyo 106, Japan.
Tel. (+81) 3-5561-5033: Fax (+81) 3-5561-5047; E-mail:
info@elsevier.co.jp <mailto:info@elsevier.co.jp >

*Copyright*

Upon acceptance of an article, authors will be asked to transfer
copyright (for more information on copyright, see External link
http://authors.elsevier.com). This transfer will ensure the widest
possible dissemination of information. A letter will be sent to the
corresponding author confirming receipt of the manuscript. A form
facilitating transfer of copyright will be provided.

If excerpts from other copyrighted works are included, the author(s)
must obtain written permission from the copyright owners and credit the
source(s) in the article. Elsevier has preprinted forms for use by
authors in these cases : contact Elsevier's Rights Department,
Philadelphia, PA, USA: Tel. (+1) 215 238 7869; Fax (+1) 215 238 2239;
e-mail healthpermissions@elsevier.com
<mailto:healthpermissions@elsevier.com>. Requests may also be completed
online via the Elsevier homepage ( External link
http://www.elsevier.com/locate/permissions).

*US National Institutes of Health (NIH) voluntary posting ("Public
Access") policy*

Elsevier facilitates author response to the NIH voluntary posting
request (referred to as the NOH "Public Access Policy"; see External
link http://www.nih.gov/about/publicaccess/index.htm) by posting the
peer-reviewed author's manuscript directly to PubMedCentral on request
from the author, 12 months after formal publication. Upon notification
from Elsevier of acceptance, we will ask you to confirm via e-mail (by
e-mailing us at NIHauthorrequest@elsevier.com
<mailto:NIHauthorrequest@elsevier.com>) that your work has received NIH
funding and that you intend to respond to the NIH policy request, along
with your NIH award number to facilitate processing. Upon such
confirmation, Elsevier will submit to PubMedCentral on your behalf a
version of your manuscripts that will include peer-review comments, for
posting 12 months after formal publication. This will ensure that you
have responded fully to the NIH request policy. There will be no need
for you to post your manuscript directly with PubMedCentral, and any
such posting is prohibited.

*Author's rights*

As an author you (or your employer or institution) may do the following :
- Make copies (print or electronic) of the article for your own personal
use, including for your own classroom teaching use.
- Make copies and distribute such copies (including through e-mail) of
the article to research colleagues, for the personal use by such
colleagues (but not commercially or systematically, e.g. via an e-mail
list or list server).
- Post a pre-print version of the article on Internet websites including
pre-print servers, and to retain indefinitely such version on such
servers or sites.
- Post a revised personal version of the final text of the article (to
reflect changes made in the peer review and editing process) on your
personal or institutional website or server, with a link to the journal
homepage (on External link http://www.elsevier.com).
- Present the article at a meeting or conference and to distribute
copies of the article to the delegates attending such a meeting.
- For your employer, if the article is a 'work for hire', made within
the scope of your employment, your employer may use all or part of the
information in the article for other intra-company use (e.g. training).
- Retain patent and trademark rights and rights to any processes or
procedure described in the article.
- Include the article in full or in part in a thesis or dissertation
(provided that this is not to be published commercially).
- Use the article or any part thereof in a printed compilation of your
works, such as collected writings or lecture notes (subsequent to
publication of your article in the journal).
- Prepare other derivative works, to extend the article into book-length
form, or to otherwise re-use portions or excerpts in other works, with
full acknowledgement of its original publication in the journal.

_ Proof reading_. When you receive a (PDF) proof (as an e-mail
attachment) of your article for correction, it is important to ensure
that all your corrections are sent back to us in one communication.
Subsequent corrections will not be possible.

_Reprints_. An electronic offprint or a total of 25 reprints of each
paper will be provided free of charge. Additional copies may be ordered
at prices shown in the reprint order form which will be sent to the author.

Author enquiries. Authors can also keep track of the progress of their
accepted article, and set up email alerts informing them of changes to
their manuscript's status, by using the "Track a Paper" feature of
Elsevier's Author Gateway ( External link http://authors.elsevier.com).

For specific enquiries on the preparation of electronic artwork, consult
External link http://authors.elsevier.com.

Contact details for questions arising after acceptance of an article,
especially those relating to proofs, are provided when an article is
accepted for publication.

/Cancer Letters/ has no page charges.

*Sponsored Articles:*
Cancer Letters offers authors or their institutions the option to
sponsor non-subscriber access to their articles on Elsevier's electronic
publishing platforms. For more information please click here
<http://www.elsevier.com/wps/find/authorshome.authors/can>.

	
		

		

		
	
Printer-friendly version <javascript:openPrinterFriendlyPage()>
  Printer-friendly version <javascript:openPrinterFriendlyPage()>

	

		

		
	
	
 Home </wps/find/homepage.cws_home> | Site map
</wps/find/sitemap.cws_home/sitemap> | Privacy policy
</wps/find/privacypolicy.cws_home/privacypolicy> | Terms and Conditions
</wps/find/termsconditions.cws_home/termsconditions> | Feedback
</wps/find/feedbackform.cws_home> | A Reed Elsevier
<http://www.reed-elsevier.com> company 	
 Copyright © 2007 Elsevier B.V. </wps/find/homepage.cws_home> All rights
reserved.

	

